Improving Soluble Expression of SARS-CoV-2 Spike Priming Protease TMPRSS2 with an Artificial Fusing Protein

Xiao Ye, Xue Ling, Min Wu, Guijie Bai, Meng Yuan, Lang RaoInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This paper tackles the challenge of producing soluble SARS-CoV-2 spike protease TMPRSS2 in E. coli, a crucial step for developing antiviral therapies. By fusing TMPRSS2 with a novel artificial protein called XXA, the researchers achieved significantly improved soluble expression and enhanced thermostability of the enzyme without compromising its catalytic activity.

What Problem Does This Paper Address?

The SARS-CoV-2 virus enters host cells by its spike protein binding to the ACE2 receptor. A critical step in this process is the priming of the spike protein by host proteases, particularly TMPRSS2, which cleaves the spike protein to enable membrane fusion. Because of its pivotal role in viral entry, TMPRSS2 is a prime target for developing antiviral drugs against coronaviruses. However, producing functional TMPRSS2 protein for research and drug development is challenging. As a mammalian-originated protein, TMPRSS2 is notoriously difficult to express in a soluble form in prokaryotic systems like E. coli, often forming insoluble inclusion bodies. This necessitates complex and time-consuming refolding procedures, hindering large-scale production and research efforts.

Methods

The researchers explored various protein engineering strategies to improve soluble TMPRSS2 expression in E. coli. They began by attempting to express a truncated version of TMPRSS2 (amino acids 106-492) fused to a His-tag, but this resulted in insoluble inclusion bodies. To overcome this, they tested three common solubility-enhancing fusion tags: SUMO, MBP, and GST. Unfortunately, these tags did not significantly improve soluble expression.

The breakthrough came with the use of XXA, an artificial protein tag developed from the retro-sequence of an antifreeze protein. XXA is known for its high solubility and hydrophilicity. The researchers fused XXA to the N-terminus of TMPRSS2, creating the XXA-TMPRSS2 construct. They then expressed this construct in E. coli and analyzed the soluble and insoluble fractions using SDS-PAGE.

To assess the functional impact of the XXA tag, they generated a tag-free version of TMPRSS2 (ΔXXA-TMPRSS2) by cleaving the XXA tag using HRV 3C protease. The enzymatic activity of both XXA-TMPRSS2 and ΔXXA-TMPRSS2 was compared using a fluorogenic substrate. Furthermore, the thermostability of the two proteins was evaluated by incubating them at elevated temperatures and measuring residual activity. Circular dichroism (CD) spectroscopy was employed to analyze the thermal denaturation profiles and determine the melting temperatures (Tm) of the proteins. Mass spectrometry (MALDI-TOF) was used to confirm the identity of the expressed protein.

Datasets

Not discussed in the paper. The study focuses on protein expression and characterization rather than training on large datasets.

Key Insights and Ideas

  • XXA is a superior solubility enhancer for TMPRSS2: While common tags like SUMO, MBP, and GST failed to yield soluble TMPRSS2, the artificial XXA tag dramatically improved its solubility in E. coli. This highlights the potential of novel, artificially designed protein tags.
  • XXA preserves and enhances TMPRSS2 function: Crucially, the XXA tag did not negatively impact the enzymatic activity of TMPRSS2. In fact, it significantly enhanced the enzyme's thermostability, making it more robust for storage and application.
  • Prokaryotic expression of TMPRSS2 is feasible with the right tag: This work demonstrates that overcoming the inclusion body problem for TMPRSS2 in E. coli is achievable, opening doors for cost-effective, large-scale production.
  • Thermostability is a valuable bonus: The improved thermal stability conferred by the XXA tag is a significant advantage, potentially simplifying handling and extending the shelf-life of the purified enzyme.

Key Results

  • Standard solubility tags (SUMO, MBP, GST) failed to produce soluble TMPRSS2 in E. coli.
  • The XXA fusion tag resulted in a 16-fold increase in proteolytic activity compared to the His-tag alone, indicating a substantial improvement in soluble, active TMPRSS2 expression.
  • XXA-TMPRSS2 showed significantly enhanced thermostability: it maintained over 80% activity after 4 hours at both 45°C and 55°C, while the tag-free version lost over 80% activity under the same conditions.
  • CD spectroscopy revealed a higher melting temperature (Tm) for XXA-TMPRSS2 (73.8 °C) compared to ΔXXA-TMPRSS2 (67.7 °C), confirming improved thermal stability.
  • Kinetic parameters (Km, kcat, Vmax) for XXA-TMPRSS2 were comparable to the tag-free enzyme, indicating that the XXA tag had a negligible impact on catalytic efficiency.

Limitations and Future Work

  • Periplasmic expression limitations: The authors briefly mention periplasmic expression as an alternative but note its limitations, such as lower productivity and more laborious extraction. Their focus on cytoplasmic expression with XXA bypasses these issues.
  • Further optimization of XXA tag: While XXA proved highly effective, further research could explore variations or alternative artificial tags for even greater solubility and stability.
  • In vivo studies: The current study focuses on in vitro characterization. Future work could investigate the efficacy of XXA-TMPRSS2 in cellular models or its potential for in vivo applications.
  • Broader applicability of XXA: The success with TMPRSS2 suggests XXA could be a valuable tool for expressing other challenging, aggregation-prone proteins in E. coli.

This research provides a significant step forward in making TMPRSS2 readily available for research, paving the way for accelerated discovery and development of much-needed anti-SARS-CoV-2 therapeutics.

Summary updated

Abstract

SARS-CoV-2 relies on the recognition of the spike protein by the host cell receptor ACE2 for cellular entry. In this process, transmembrane serine protease 2 (TMPRSS2) plays a pivotal role, as it acts as the principal priming agent catalyzing spike protein cleavage to initiate the fusion of the cell membrane with the virus. Thus, TMPRSS2 is an ideal pharmacological target for COVID-19 therapy development, and the effective production of high-quality TMPRSS2 protein is essential for basic and pharmacological research. Unfortunately, as a mammalian-originated protein, TMPRSS2 could not be solubly expressed in the prokaryotic system. In this study, we applied different protein engineering methods and found that an artificial protein XXA derived from an antifreeze protein can effectively promote the proper folding of TMPRSS2, leading to a significant improvement in the yield of its soluble form. Our study also showed that the fused XXA protein did not influence the enzymatic catalytic activity; instead, it greatly enhanced TMPRSS2's thermostability. Therefore, our strategy for increasing TMPRSS2 expression would be beneficial for the large-scale production of this stable enzyme, which would accelerate aniti-SARS-CoV-2 therapeutics development.
BibTeX
@article{ye2023improving,
  author = {Xiao Ye and Xue Ling and Min Wu and Guijie Bai and Meng Yuan and Lang Rao},
  title = {{Improving Soluble Expression of SARS-CoV-2 Spike Priming Protease TMPRSS2 with an Artificial Fusing Protein}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310475},
}
Figure